Royalty Report: Drugs, Pharmaceuticals, Multiple Sclerosis – Collection: 1365

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Multiple Sclerosis
  • Therapeutic
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 1365

License Grant
The Irish Licensor completed the asset purchase transaction with the Licensee, whereby the Licensor transferred to the Licensee all Tysabri IP and other assets related to Tysabri.
License Property
Tysabri is a laboratory-produced monoclonal antibody. It is designed to hamper movement of potentially damaging immune cells from the bloodstream, across the “blood-brain barrier” into the brain and spinal cord.
Field of Use
Tysabri is used in the treatment of multiple sclerosis and Crohn's disease.

IPSCIO Record ID: 28719

License Grant
Pursuant to an asset purchase agreement, the Company acquired two definite-lived intangible assets in the acquisition, both of which are exclusive technology agreements.  This agreement is for Tysabri®.
License Property
The property included assets focused on the treatment of Multiple Sclerosis (Tysabri®).
Field of Use
The field of use is for all indications and geographies.

IPSCIO Record ID: 316237

License Grant
Under the terms of the Asset Purchase Agreement with Party A, the Danish Licensee became party to a royalty agreement with the Trust for worldwide net sales of Arimoclomol for the treatment of Amyotrophic Lateral Sclerosis (ALS). Pursuant to this Asset Agreement, Party A sold and transferred certain preclinical and clinical data, patents and other intellectual property rights, and other assets, including contractual rights and obligations relating to a portfolio of chemical compounds, including arimoclomol, to Licensee.
License Property
Arimoclomol is an orally- or naso/gastrically-administered small molecule that crosses the blood-brain barrier and is designed to selectively amplify the natural role of endogenous Heat Shock Proteins (HSPs), which protect against cellular toxicity caused by protein misfolding, aggregation and lysosomal dysfunction.

The Trust is the charitable remainder beneficiary that generates a potential income stream from donors, or other beneficiaries, to benefit the research of ALS.

Amyotrophic lateral sclerosis or ALS, is a progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control. ALS is often called Lou Gehrig's disease.

Field of Use
The Field of Use is for the treatment or prevention of Amyotrophic Lateral Sclerosis (ALS).  ALS, commonly referred to as Lou Gehrig’s disease, is a rapidly progressing neurological disease with the onset of symptoms typically occurring between 40 to 70 years of age, with patient mortality occurring in most patients within three to five years of disease onset. ALS attacks neurons responsible for controlling voluntary muscles, resulting in muscle weakness in limbs, and impacts speaking, chewing, swallowing and breathing, leading to progressive disability and eventually death, typically from respiratory failure and aspiration pneumonia.

Licensee is biopharmaceutical company harnessing the amplification of Heat Shock Proteins, or HSPs, in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases that includes Amyotrophic Lateral Sclerosis (ALS), commonly referred to as Lou Gehrig’s disease.

IPSCIO Record ID: 994

License Grant
An Irish Pharma has cured an unintended breach of its Tysabri (natalizumab) collaboration agreement with another company that had been identified by the US District Court for the Southern District of New York. This affected a previously-announced transaction with a large U.S. based pharma which has now been amended to eliminate in its entirety, the strategic financing and collaboration agreement that was the subject of the Court's 3rd September hearing and the previously-disclosed notice of breach.

Licensee will acquire substantially all of the business, assets and rights related to licensor's Alzheimer's Immunotherapy Program, through a newly-formed company and will initially commit funds to continue the development and launch activities of bapineuzumab, a potential first-in-class treatment that is being evaluated for slowing the progression of Alzheimer's disease, as well as other compounds.

Field of Use
The rights granted apply to the healthcare industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.